Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Aptinyx Evaluates Strategic Alternatives For Its Future After Failed Trials, 60% Layoffs

In March, Aptinyx Inc (NASDAQ:APTX) completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical…
byVandana Singh
March 31, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • In March, Aptinyx Inc (NASDAQ:APTX) completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). 
  • The study was halted in February before its completion to support the company’s capital preservation. 
  • In the analysis, NYX-783 did not demonstrate sufficient improvement on the study’s primary endpoint to support the continued advancement of the development program by Aptinyx.
  • The company is working with Ladenburg Thalmann as its financial advisor to assist in exploring and evaluating “strategic alternatives.”
  • In March, Aptinyx reduced its workforce by approximately 60%.
  • Aptinyx reported cash and cash equivalents at $56.2 million as of Dec. 31. The company had $25.0 million of debt principal under a capital credit facility with K2 HealthVentures, which remains currently outstanding.
  • Last year, the company had another setback when its study in patients with advanced painful diabetic peripheral neuropathy showed its drug couldn’t beat the placebo.
  • In February, the company announced that its Phase 2 study evaluating the effects of NYX-458 did not demonstrate clinically meaningful improvements over the placebo on the study’s efficacy endpoints in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
  • Price Action: APTX shares are down 4.12% at $0.1280 on the last check Friday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Biomerica Receives Notice Of Patent Allowance In China For A Potential Innovative Technology That Includes An Artificial Intelligence Claim For Predicting Foods That Contain Ingredients That Cause Adverse Reactions In Patients

By Happy Mohamed
June 21, 8:24 AM
Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical Data   The Patent further describes Algorithms to help Determine Safety Levels of Food Ingredients,

BMEA

Read More

Colgate-Palmolive Has Strong Brand-Building And Analytics-Driven Marketing Strategy, Says Analyst

By Shivani Kumaresan
April 29, 1:34 PM
BofA Securities analyst Bryan Spillane boosts Colgate-Palmolive's target to $100, citing impressive growth metrics. CL started the year strong with +9.8% organic sales and EPS of $0.86, beating estimates. Pricing surged +8.5%, driving a significant margin expansion. Hyperinflation in select regions fueled performance, while North America saw notable market share gains, a testament to Colgate's marketing prowess.

CL

Read More

Mullen Streamlines Business Operations To Focus On Near Term Commercial Opportunities, Actions Are Expected To Drive An Estimated $170M Reduction In The Co’s Operating And Investing Cash Flow Expenses Over The Next 12 Months When Compared YoY

By Benzinga Newsdesk
April 8, 8:43 AM
Cost saving initiatives aimed at reducing operating and investing cash flows by approximately $170 million over the next 12 months when compared to operating and investing cash flows reported for the 12 months ended

MULN